The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled,... by Kulkarni, PS, Potey, AV, Bharati, S, Kunhihitlu, A, Narasimha, B, Yallapa, S, Dharmadhikari, A, Gavade, V, Kamat, CD, Mallya, A, Sarma, AD, Goel, S, Pisal, SS, Poonawalla, CS, Venkatesan, R, Jones, E, Flaxman, A, Kim, YC, Pollard, AJ

“…The seroconversion rates on day 29 were 96·7% (95% CI 82·8–99·9) with Sii-PTCV and 100·0% (88·4–100·0) with Typbar-TCV for anti-Vi IgG; 93·3% (77·9–99·2) with Sii-PTCV and 100·0% (88·4–100·0) with Typbar-TCV for anti-Vi IgA; 100·0% (88·4–100·0) with Sii-PTCV and 3·3% (0·1–17·2) with Typbar-TCV for anti-LPS (paratyphoid); and 93·3% (77·9–99·2) with Sii-PTCV and 0% (0·0–11·6) with Typbar-TCV for SBA titres (paratyphoid). …”